We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

54 hedge funds and large institutions have $443M invested in RAPT Therapeutics in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 4

400% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 4

77% more capital invested

Capital invested by funds: $250M → $443M (+$192M)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

42% more funds holding

Funds holding: 3854 (+16)

1.65% more ownership

Funds ownership: 6.06%7.71% (+1.6%)

Holders
54
Holders Change
+16
Holders Change %
+42.11%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
20
Increased
24
Reduced
4
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of Montreal
51
Bank of Montreal
Ontario, Canada
$23K +$16.4K +106 +10,600%
Nisa Investment Advisors
52
Nisa Investment Advisors
Missouri
$10K +$3.56K +23 +128%
Osaic Holdings
53
Osaic Holdings
Arizona
$4K
LM
54
Luminus Management
Texas
-$5.68M -33,409 Closed
ECM
55
ExodusPoint Capital Management
New York
-$295K -1,735 Closed
UOC
56
UBS O'Connor
Illinois
-$213K -1,250 Closed
Federated Hermes
57
Federated Hermes
Pennsylvania
-$14K -82 Closed
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
-$9.74K -63 -98%

RAPT Hedge Fund Activity: Q2 2020 in Review

54 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2020, worth a combined $443M — up 77% from $250M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RAPT positions and 4 closed out — a net gain of 16 holders — while 24 added to existing stakes and 4 trimmed.

The largest buyer was Regents of the University of California, opening a new position worth an estimated $30.4M. The largest seller was Luminus Management, exiting entirely with an estimated $5.68M sold.

  • 54 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2020, up from 38 in Q1 2020.
  • Funds reported $443M of RAPT Therapeutics stock for Q2 2020, up 77% quarter-over-quarter.
  • 20 funds opened new RAPT Therapeutics positions in Q2 2020 and 4 closed out, a net change of +16 holders.
  • The largest RAPT Therapeutics buyer in Q2 2020 was Regents of the University of California, an estimated $30.4M added.
  • The largest RAPT Therapeutics seller in Q2 2020 was Luminus Management, an estimated $5.68M sold.

Based on aggregated 13F filings for Q2 2020.